Julia Davydova
,
Credentials
MD, PhD
Bio
Dr. Davydova is an Associate Professor at the Department of Surgery at the University of Minnesota (UMN). She is also a faculty member at the UMN Institute for Molecular Virology, Masonic Cancer Center, Center for Genome Engineering, and MD/PhD Medical Scientist Training Program.
Dr. Davydova has over 20 years of experience in the field of gene therapy and cancer research. As a member of the Gene Therapy Center at the University of Alabama at Birmingham (UAB), she was directly involved in the development of first generations of adenoviral vectors for malignant diseases and establishment of standardized procedures for virus manufacturing. Her scientific contribution has resulted in developing critical elements to improve infectivity and specificity of adenovirus-based vectors which extended their utility for human gene therapy.
Since joining the Department of Surgery and the Masonic Cancer Center at the UMN in 2006, Dr. Davydova’s research is focused on the clinical translation of adenovirus-based technologies for cancer patients. Her work with a focus on oncolytic adenovirus-mediated therapies for pancreatic cancer was funded by multiple awards including two NIH R01 grants.
Dr. Davydova is a member of several professional societies, including American Society of Gene and Cell Therapy, American Association of Cancer Research, American Pancreatic Association and serves as an Academic and/or Guest editor in professional journals. She is also actively participating as a reviewer at multiple NIH study sections (e.g., Translational Immuno-Oncology (TIO), Radiation Therapeutics and Biology (RTB), Clinical and Translational Exploratory/Developmental Studies) and many international grant review panels.
Dr. Davydova is a productive mentor to numerous laboratory trainees at different levels including undergrad and graduate students, medical scholars, postdoctoral fellows, surgical residents, and junior faculty.
Education
Dr. Davydova received her M.D. and Ph.D. in Pathophysiology and Molecular Biology from the Siberian State Medical University in Tomsk, Russia. In 2000, she was invited to join the Gene Therapy Center at the University of Alabama at Birmingham (UAB), where she obtained extensive training in virus-based gene therapy and cancer research.
Research Summary
Dr. Davydova’s current goals are focused on the clinical translation of oncolytic adenovirus for cancer patients, including patients with pancreatic, breast, melanoma, and sarcoma malignances.
Her research focus includes but is not limited to:
- Development of oncolytic adenovirus as a platform for cancer therapy and imaging.
- Development of novel virus-based immunotherapies for cancer patients.
- Clinical translation of oncolytic adenovirus from “bench to bed”.
- Development of immunocompetent preclinical models for oncolytic virus therapy and cancer research.
Selected Publications
- Osipov, I. D., Vaskihovskaia, V. A., Zabelina, D. S., Kutseikin, S. S., Grazhdantseva, A. A., Kochneva, G. V., Davydova, J., Netesov, S. V., Romanenko, M. V. (2023). Development of Oncolytic Vectors Based on Human Adenovirus Type 6 for Cancer Treatment. Viruses 2023, 15 (1), 182. doi: 10.3390/v1510182
- Romanenko, M., Osipov, I., Netesov, S. V., Davydova, J. (2021). Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy. Pharmaceutics, 13(10). PMID: 34683934 PMCID: PMC8540711 doi: 10.3390/pharmaceutics13101641
- Robertson, M. G., Eidenschink, B. B., Iguchi, E., Zakharkin, S. O., LaRocca, C. J., Tolosa, E. J., Truty, M. J., Jacobsen, K., Fernandez-Zapico E., Davydova, J. (2021). Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion. Mol Ther Oncolytics(5;20), 659-668. PMID: 33816784 PMCID: PMC7985464 doi: 10.1016/j.omto.2021.03.002
- Koodie, L., Robertson, M. G., Chandrashekar, M., Ruth, G., Dunning, M., Bianco, R. W., Davydova, J. (2019). Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses. Cancers, 11(2). PMID: 30744019 PMCID: PMC6406826 doi: 10.3390/cancers11020198
- Shapovalova, M., Davydova, J., Henzler, C., Daniel, M., Dehm, S. M., Warlick, C. A., LeBeau, A. M. (2018). Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer. Oncotarget, 9(94), 36693-36704. PMID: 30613352 PMCID: PMC6291171 doi: 10.18632/oncotarget.26401
- Salzwedel, A. O., Han, J., LaRocca, C. J., Shanley, R., Yamamoto, M., Davydova, J. (2018). Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer. Oncotarget, 9(26), 18041-18052. PMID: 29719589 PMCID: PMC5915056 doi: 10.18632/oncotarget.24710
- LaRocca, C. J., Davydova, J. (2016). Oncolytic Virotherapy Increases the Detection of Microscopic Metastatic Disease at Time of Staging Laparoscopy for Pancreatic Adenocarcinoma. EBioMedicine, 7, 15-6. PMID: 27322450 PMCID: PMC4909609 doi: 10.1016/j.ebiom.2016.05.019
- Tasca, A., Stemig, M., Broege, A., Huang, B., Davydova, J., Zwijsen, A., Umans, L., Jensen, E. D., Gopalakrishnan, R., Mansky, K. C. (2015). Smad1/5 and Smad4 expression are important for osteoclast differentiation. Journal of cellular biochemistry, 116(7), 1350-60. PMID: 25711193 PMCID: PMC4431909 doi: 10.1002/jcb.25092
- LaRocca, C. J., Han, J., Gavrikova, T., Armstrong, L., Oliveira, A. R., Shanley, R., Vickers, S. M., Yamamoto, M., Davydova, J. (2015). Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery, 157(5), 888-98. PMID: 25731784 PMCID: PMC4417428 doi: 10.1016/j.surg.2015.01.006
- Davydova, J., Yamamoto, M. (2013). Oncolytic adenoviruses: design, generation, and experimental procedures. Current protocols in human genetics, Chapter 12, Unit 12.14. PMID: 23853080 doi: 10.1002/0471142905.hg1214s78
- Mansky, K. C., Jensen, E. D., Davydova, J., Yamamoto, M., Gopalakrishnan, R. (2013). Protein Kinase D Promotes In Vitro Osteoclast Differentiation and Fusion. J Biol Chem, 288(14), 9826-9834.
- Oneal, M. J., Trujillo, M. A., Davydova, J., McDonough, S., Yamamoto, M., Morris, 3rd, J. C. (2013). Effect of increased viral replication and infectivity enhancement on radioiodide uptake and oncolytic activity of adenovirus vectors expressing the sodium iodide symporter. Cancer gene therapy, 20(3), 195-200. PMID: 23412431 doi: 10.1038/cgt.2013.4
- Miura, Y., Yamasaki, S., Davydova, J., Brown, E., Aoki, K., Vickers, S., Yamamoto, M. (2013). Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Molecular therapy : the journal of the American Society of Gene Therapy, 21(1), 139-48. PMID: 23032977 PMCID: PMC3538312 doi: 10.1038/mt.2012.205
- Armstrong, L., Arrington, A., Han, J., Gavrikova, T., Brown, E., Yamamoto, M., Vickers, S. M., Davydova, J. (2012). Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. American journal of surgery, 204(5), 741-50. PMID: 22748294 PMCID: PMC3467355 doi: 10.1016/j.amjsurg.2012.02.016
- Oneal, M. J., Trujillo, M. A., Davydova, J., McDonough, S., Yamamoto, M., Morris, 3rd, J. C. (2012). Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy. Human gene therapy, 23(9), 951-9. PMID: 22694073 PMCID: PMC3440023 doi: 10.1089/hum.2012.047
- Pham, L., Beyer, K., Jensen, E. D., Rodriguez, J. S., Davydova, J., Yamamoto, M., Petryk, A., Gopalakrishnan, R., Mansky, K. C. (2011). Bone morphogenetic protein 2 signaling in osteoclasts is negatively regulated by the BMP antagonist, twisted gastrulation. Journal of cellular biochemistry, 112(3), 793-803. PMID: 21328453 PMCID: PMC3335346 doi: 10.1002/jcb.23003
- Davydova, J., Gavrikova, T., Brown, E. J., Luo, X., Curiel, D. T., Vickers, S. M., Yamamoto, M. (2010). In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer science, 101(2), 474-81. PMID: 19900190 PMCID: PMC4584507 doi: 10.1111/j.1349-7006.2009.01407.x
- RamĂrez, P. J., Vickers, S. M., Ono, H. A., Davydova, J., Takayama, K., Thompson, T. C., Curiel, D. T., Bland, K. I., Yamamoto, M. (2008). Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. American journal of surgery, 195(4), 481-90. PMID: 18361926 doi: 10.1016/j.amjsurg.2007.04.014
- Le, L. P., Le, H. N., Dmitriev, I. P., Davydova, J. G., Gavrikova, T., Yamamoto, S., Curiel, D. T., Yamamoto, M. (2006). Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. Journal of the National Cancer Institute, 98(3), 203-14. PMID: 16449680 doi: 10.1093/jnci/djj022
- Davydova, J., Le, L. P., Gavrikova, T., Wang, M., Krasnykh, V., Yamamoto, M. (2004). Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer research, 64(12), 4319-27. PMID: 15205347 doi: 10.1158/0008-5472.CAN-04-0064
- Le, L. P., Everts, M., Dmitriev, I. P., Davydova, J. G., Yamamoto, M., Curiel, D. T. (2004). Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Molecular imaging, 3(2), 105-16. PMID: 15296675 doi: 10.1162/1535350041464874
- Yamamoto, M., Davydova, J., Wang, M., Siegal, G. P., Krasnykh, V., Vickers, S. M., Curiel, D. T. (2003). Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology, 125(4), 1203-1218. doi: 10.1016/S0016-5085(03)01196-X
Selected Presentations
Contact
Address
Division of Basic & Translational Research, Department of Surgery, University of Minnesota420 Delaware St. SE - MMC 195
Minneapolis, MN 55455
Administrative Contact
Kelli Tourand |Â Â 612-624-4581 |Â toura018@umn.edu